June Election: FDA Reproductive Health Drugs Panel Holds On To Hager For Second Term
This article was originally published in The Pink Sheet Daily
Executive Summary
Plan B OTC opponent Hager reappointed to FDA’s Reproductive Health Drugs Advisory Committee, effective June 30. Hager’s term was renewed for another year after an unusually short previous appointment expired and despite an effort by several House members to block his reappointment.